News

Johnson & Johnson Submits Schizophrenia Drug CAPLYTA sNDA to FDA Based on Positive Relapse Prevention Data
Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...
Forecasting The Future: 8 Analyst Projections For Johnson & Johnson
In the assessment of 12-month price targets, analysts unveil insights for Johnson & Johnson, presenting an average target of $168.25, a high estimate of $181.00, and a low estimate of $153.00.
Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Dividend Stock Instead?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Johnson & Johnson's Outlook Clouded By $2 Billion Headwind
Johnson & Johnson's 2025 outlook sees slight EPS and revenue upgrades, while headwinds from biosimilars and tariffs are ...
Wizards draftee Tre Johnson has no time for rest: ‘He wants to be great’
What can the Wizards expect from the 2025 draft's sixth pick? He'll be "an old-school throwback kind of guy" and an elite ...